819 Capital Partnership News – Amsterdam-based 819 Capital Partners has Acquired CiMaas

CiMaas had filed for bankruptcy on June 11, 2024, due to financial difficulties that prevented it from funding essential clinical studies, despite having advanced NK cell technology.

Read also - Taito.ai funding news - Helsinki-based Taito.ai has Secured €2.5 Million in Seed Funding

After the acquisition, CiMaas remains committed to its goal of developing effective, low-side-effect cancer treatments, with a focus on GMP-grade NK cells.

CiMaas mentions in a statement, “Thanks to an investment from 819 Evergreen Fund I, we are pleased to be able to continue working on our ambitions: cure cancer patients by making Natural Killer cells a reality. Our activities will be realised in Maastricht.”

Gerard Bos, CEO of CiMaas, says, “We are pleased to partner with 819 Capital Partners. This investment enables us to continue working on our ambitions: cure cancer patients by making Natural Killer cells a reality. Our commitment to advancing cell-therapy opportunities for cancer treatment remains as strong as ever, and we are very motivated to continue our work in this vital field now In the coming period, we will further strengthen our team with highly skilled professionals.”

819 Capital Partners is an investment firm that focused on venture capital, private equity and corporate finance, aiming to drive innovation and growth in key sectors.

The firm focuses on healthcare, technology, and leisure and recently launched the 819 Evergreen Fund to invest in early-stage deeptech companies. It also helps businesses grow through private equity investments and buy-and-build strategies.

With over €60M in assets and 14 active portfolio companies generating €500M in revenue, the firm provides direct support to entrepreneurs to help them achieve their growth goals.

About CiMaas

CiMaas was founded in 2015 as a spin-off from Maastricht University and Maastricht University Medical Center+. The company focuses on transforming cancer treatment using immunotherapies, which aim to use the body’s immune system to treat metastatic and late-stage cancers. These therapies aim to fill gaps in areas where current treatments are often ineffective, especially in advanced stages of cancer.